Recurrent Grade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recurrent Grade. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recurrent Grade Today - Breaking & Trending Today

INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation

Published: June 21, 2023

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

Source: onclive.com

Related Topics:

Timothy CloughesyDouble Blinded StudyRecurrent GradePartnership With